Advances in the Treatment of Glucocorticoid Resistance and Relapsed Immune Thrombocytopenia --Review.
10.19746/j.cnki.issn.1009-2137.2023.02.047
- Author:
Hui-Min PAN
1
;
Rui-Ting WEN
1
;
Zhi-Gang YANG
2
Author Information
1. Department of Hematology, Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang 524045, Guangdong Province, China.
2. Department of Hematology, Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang 524045, Guangdong Province, China.E-mail:yangzg@gdmu.edu.cn.
- Publication Type:Journal Article
- Keywords:
immune thrombocytopenia;
immunomodulator;
relapsed/refractory;
demethylating agents
- MeSH:
Infant, Newborn;
Humans;
Purpura, Thrombocytopenic, Idiopathic/drug therapy*;
Glucocorticoids/therapeutic use*;
Thrombocytopenia;
Immunoglobulins, Intravenous/therapeutic use*;
Immunologic Factors/therapeutic use*
- From:
Journal of Experimental Hematology
2023;31(2):616-620
- CountryChina
- Language:Chinese
-
Abstract:
Immune thrombocytopenia (ITP) is an immune-mediated acquired hemorrhagic autoimmune disease. At present, the first-line therapeutic drugs for ITP include glucocorticoids and intravenous immunoglobulins. However, about 1/3 of the patients had no response to the first-line treatment, or relapsed after dose reduction or withdrawal of glucocorticoids. In recent years, with the gradual deepening of the understanding on the pathogenesis of ITP, the drugs targeting different pathogenesis continually emerge, including immunomodulators, demethylating agents, spleen tyrosine kinase (SYK) inhibitors and neonatal Fc receptor (FcRn) antagonist. However, most of these drugs are in clinical trials. This review summarized briefly the recent advances in the treatment of glucocorticoids resistance and relapsed ITP, so as to provide reference for the clinical treatments.
